Skip to main content

Advertisement

Table 1 Characteristics of patients treated with SGN-CD33A by genotype

From: CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A

  CC (n=10)  CT/TT (n=10)  Total (n=20) p value
Gender     0.361
 Female 5 (50.0%) 7 (70.0%) 12 (60.0%)  
 Male 5 (50.0%) 3 (30.0%) 8 (40.0%)  
Age     0.418
 Mean (range) 67.3 (27.5-80.0) 72.3 (42.0 -82.6) 69.8 (27.5-82.6)  
ECOG     0.160
 0 2 (20.0%) 5 (50.0%) 7 (35.0%)  
 1 8 (80.0%) 5 (50.0%) 13 (65.0%)  
Risk group     0.148
 Adverse 7 (70.0%) 4 (40.0%) 11 (55.0%)  
 Favorable 1 (10.0%) 0 (0.0%) 1 (5.0%)  
 Intermed. 2 (20.0%) 6 (60.0%) 8 (40.0%)  
BM blast %     0.334
 Median (Q1, Q3) 64.0 (43.2, 80.0) 54.0 (24.0,66.0) 56.0 (36.0,78.0)  
WBC     0.200
 Mean (SD) 13.6 (17.1) 5.6 (8.1) 9.6 (13.7)  
 Median (Q1, Q3) 5.3 (1.7, 16.5) 1.7 (1.2, 3.8) 2.5 (1.5, 16.4)  
 Range 0.8 - 51.7 0.4 - 23.1 0.4 - 51.7  
 IQR 14.8 2.7 14.9  
Platelets     0.913
 Mean (SD) 50.3 (41.2) 52.4 (43.9) 51.4 (41.5)  
 Median (Q1, Q3) 34.0 (22.0, 75.0) 32.0 (21.8,90.8) 34.0 (19.8,89.5)  
 Range 11.0 - 133.0 5.0 - 116.0 5.0 - 133.0  
 IQR 53.0 69.0 69.8  
De novo     0.531
 Yes 1 (10.0%) 2 (20.0%) 3 (15.0%)  
 No 9 (90.0%) 8 (80.0%) 17 (85.0%)  
Line of tx     0.361
 1st 3 (30.0%) 5 (50.0%) 8 (40.0%)  
 2nd 7 (70.0%) 5 (50.0%) 12 (60.0%)  
  1. BM bone marrow, ECOG Eastern Cooperative Oncology Group, IQR interquartile range, tx treatment, WBC white blood cell